Accelerate to discover

Back to filter

Related topics

Standardize tumor sample preparation and reduce background with Curiox laminar wash system

Curiox

Aug 10, 2022

Laminar Wash technology offers a gentle alternative that can improve yield and data quality, particularly of rare cell...

Developing a 43 color panel on Cytek Aurora using Laminar Wash for sample prep

Curiox

Aug 2, 2022

Successfully executing a 43 color panel is a technically demanding task. One that is made more difficult when there are...

Intoducing spheroOne: Automated sorting and isolation of single spheroids and organoids

Cellenion

Jun 21, 2022

spheroONE is an innovative single large-particle sorter and dispenser which revolutionizes 3D cellular models handling....

Outstanding post-sort sample recovery on the WOLF Cell Sorter

NanoCellect

Jun 14, 2022

The new WOLF G2 instrument has significantly expanded the capabilities of gentle benchtop microfluidic cell sorting...

Aug 12, 2022

Incucyte AI module: Advanced Label-Free Classification Analysis

Sartorius & Essen BioScience

Jun 6, 2022

Monitor adherent cell morphology changes objectively to determine live/dead cell counts or classify cells based on...

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters

MOLECUBES

Jun 3, 2022

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine...

An experimental strategy for preparing circular ssDNA virus genomes for next-generation sequencing

Sage Science

Jun 1, 2022

Recent article from February 2022 shoes how size selection improved viral read mapping by over 90% for begomoviruses.

Aug 12, 2022

Intoducing cellenONE: The revolutionary Single Cell isolator

Cellenion

May 25, 2022

A revolutionary platform based on sciDROP PICO precision dispensing technology and coupled with advanced image...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey